Nanobiotix Files Routine 6-K Report
Ticker: NBTX · Form: 6-K · Filed: Dec 11, 2024 · CIK: 1760854
Sentiment: neutral
Topics: reporting, sec-filing, foreign-private-issuer
Related Tickers: NBTX
TL;DR
Nanobiotix (NBTX) filed a standard 6-K, no major news yet.
AI Summary
Nanobiotix S.A. filed a Form 6-K on December 11, 2024, to report information for the month of December 2024. The company, based in Paris, France, is a pharmaceutical preparations company and is submitting its report under the 1934 Securities Exchange Act. This filing is routine and does not appear to contain specific financial or operational updates beyond its classification.
Why It Matters
This filing indicates Nanobiotix S.A. is fulfilling its reporting obligations as a foreign private issuer. Investors should monitor future filings for specific operational or financial disclosures.
Risk Assessment
Risk Level: low — This is a routine filing by a foreign private issuer and does not contain specific material news or financial updates.
Key Players & Entities
- Nanobiotix S.A. (company) — Registrant
- 001-39777 (company) — SEC File Number
- 20241211 (date) — Filing Date
- December 2024 (date) — Reporting Period
- 60 Rue de Wattignies, 75012 Paris, France (location) — Principal Executive Office
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K is a Report of Foreign Private Issuer filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of December 2024.
What is Nanobiotix S.A.'s SEC file number?
Nanobiotix S.A.'s SEC file number is 001-39777.
Where is Nanobiotix S.A. located?
Nanobiotix S.A.'s principal executive office is located at 60 Rue de Wattignies, 75012 Paris, France.
Does Nanobiotix S.A. file annual reports under Form 20-F or 40-F?
Nanobiotix S.A. indicates it files annual reports under cover of Form 20-F.
What is the SIC code for Nanobiotix S.A.?
The Standard Industrial Classification (SIC) code for Nanobiotix S.A. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 172 words · 1 min read · ~1 pages · Grade level 9.1 · Accepted 2024-12-11 16:15:04
Filing Documents
- f6k_121024.htm (6-K) — 5KB
- exh_991.htm (EX-99.1) — 8KB
- 0001171843-24-006878.txt ( ) — 13KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Nanobiotix S.A. (Registrant) Date: December 11, 2024 /s/ Bart Van Rhijn Bart Van Rhijn Chief Financial Officer